{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T09:43:01Z","timestamp":1772012581793,"version":"3.50.1"},"reference-count":28,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2011,11,15]],"date-time":"2011-11-15T00:00:00Z","timestamp":1321315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2012,7]]},"abstract":"<jats:sec>\n                    <jats:label\/>\n                    <jats:p>Study Type \u2013 Therapy (case series)<\/jats:p>\n                    <jats:p>Level of Evidence\u20034<\/jats:p>\n                    <jats:p>\n                      <jats:bold>What's known on the subject? and What does the study add?<\/jats:bold>\n                    <\/jats:p>\n                    <jats:p>Thulium VapoEnucleation of the prostate (ThuVEP) has been introduced as a minimally invasive treatment modality of benign prostate obstruction (BPO). This study reports the largest series of patients with symptomatic BPO undergoing ThuVEP. Efficacy of this procedure was confirmed by prostate volume and PSA measurements at 12\u2010month follow up, which have not been reported after ThuVEP so far.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>To evaluate the safety and efficacy of 120\u2010W 2\u2010\u00b5m thulium:yttrium\u2013aluminium\u2013garnet (YAG) vapoenucleation of the prostate (ThuVEP) for patients with symptomatic benign prostatic obstruction.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHOD<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>In total, 207 consecutive patients undergoing ThuVEP at our institution were evaluated prospectively. ThuVEP was carried out using the 120\u2010W 2\u2010\u00b5m continuous\u2010wave Tm:YAG laser. The enucleated tissue was then morcellated within the bladder.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Patient demographic, perioperative and 12\u2010month follow\u2010up data were analysed. The complications were assessed.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>Mean preoperative prostate volume was 57.8 \u00b1 31.5\u2003mL. Total operation duration averaged 64.9 \u00b1 29.9\u2003min, and the enucleation time was 36.5 \u00b1 20.1\u2003min. The mean catheter time was 2.2 \u00b1 0.6 days.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Thirteen (6.28%) patients required a second\u2010look operation in the immediate postoperative course (failed morcellation\n                            <jats:italic>n<\/jats:italic>\n                            = 1, clot retention\n                            <jats:italic>n<\/jats:italic>\n                            = 4, residual tissue at the apex of the prostate\n                            <jats:italic>n<\/jats:italic>\n                            = 8). Four patients needed blood transfusions (1.93%) postoperatively. In all, 147 (71%) patients were available for review at the 12\u2010month follow\u2010up mark.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Quality of life (4.4 \u00b1 1.3 vs 1.2 \u00b1 1.1), international prostate symptom score (21.9 \u00b1 7.2 vs 5.1 \u00b1 4), maximum urinary flow rate (9.4 \u00b1 3.8 vs 23.5 \u00b1 10.9\u2003mL\/s), postvoiding residual urine (159.2 \u00b1 153.2 vs 26.7 \u00b1 38.3\u2003mL), prostate\u2010specific antigen (5.0 \u00b1 5.2 vs 0.6 \u00b1 0.5\u2003ng\/mL) and prostate volume (57.8 \u00b1 31.5 vs 10.7 \u00b1 4.4\u2003mL) changed significantly (\n                            <jats:italic>P<\/jats:italic>\n                            = 0.000).\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Median prostate\u2010specific antigen reduction and prostate volume reduction were 87% and 80% respectively at follow\u2010up. Urethral stricture and bladder neck contracture developed in 1.45% and 1.93% respectively of the patients.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>120\u2010W ThuVEP is a safe and efficacious procedure for the treatment of symptomatic benign prostatic obstruction. The incidence of complications with ThuVEP was low.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2011.10767.x","type":"journal-article","created":{"date-parts":[[2011,11,16]],"date-time":"2011-11-16T06:39:25Z","timestamp":1321425565000},"page":"96-101","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["120\u2010W 2\u2010\u00b5m thulium:yttrium\u2013aluminium\u2013garnet vapoenucleation of the prostate: 12\u2010month follow\u2010up"],"prefix":"10.1111","volume":"110","author":[{"given":"Christopher","family":"Netsch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Pohlmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas R.W.","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas J.","family":"Gross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thorsten","family":"Bach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,11,15]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.03.028"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2010.06.005"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.08.036"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.04.003"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.04.052"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.08.015"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-008-0370-0"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-009-0461-6"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2007.07341.x"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-007-0171-x"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.05.019"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2009.07.1266"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2009.09059.x"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000140501.68841.a1"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000136218.11998.9e"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.04.002"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2006.05898.x"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000170230.26743.e4"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000070686.56806.a1"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.06.006"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2008.03.058"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2006.11.062"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2007.06867.x"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.03.070"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2008.12.052"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365590410015858"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000092035.16351.9d"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2004.12.010"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2011.10767.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2011.10767.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T18:15:45Z","timestamp":1761761745000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2011.10767.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,15]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["10.1111\/j.1464-410X.2011.10767.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2011.10767.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,15]]},"assertion":[{"value":"2011-11-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}